In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Aeterna Zentaris (AEZS – Research Report), with a price target of $28.00. The company’s shares closed yesterday at $3.00.
According to TipRanks, Pachaiyappan is ranked #3881 out of 8325 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aeterna Zentaris with a $28.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.65 and a one-year low of $2.32. Currently, Aeterna Zentaris has an average volume of 16.24K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
Read More on AEZS:
- Aeterna Zentaris Reports First Quarter 2023 Financial Results
- AEZS Upcoming Earnings Report: What to Expect?
- Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
- Aeterna Zentaris issued notice of allowance for USPTO for macimorelin patent
- Aeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
